"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT01096082","Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3",,"Completed","No Results Available","Spinocerebellar Ataxia Type 3|Machado Joseph Disease","Drug: Lithium Carbonate|Drug: Placebo","Phase 2 - Safety and tolerability of Lithium Carbonate treatment in patients with SCA3|Phase 3 - Efficacy of Lithium Carbonate treatment in patients with SCA3|Efficacy of Lithium Carbonate in patients with SCA3 on neurological function, ataxic, depressive and quality of life scores|Effect of Lithium Carbonate treatment in peripheral levels and expression of treatment biomarkers","Hospital de Clinicas de Porto Alegre","All","16 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","09-418|HCPA FIPE GPPG: 09-418","May 2011","December 2012","January 2013","March 30, 2010","null","January 30, 2013","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil","","https://ClinicalTrials.gov/show/NCT01096082"
